Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724831 | 0.92 | NR1H2 (0.48) | CA1CA2CA9CA4NR1H2 | |
| SCHEMBL723239 | 0.91 | SMN1; SMN2 (0.42) | CA1CA2CA9CA4HTT | |
| SCHEMBL786748 | 0.90 | NR1H2 (0.45) | CA1CA2CA9CA4HTT | |
| SCHEMBL724132 | 0.88 | GABRA2 (0.46) | CA1CA2CA9CA4HTT | |
| SCHEMBL723782 | 0.88 | USP2 (0.46) | HTR6USP2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL786733 | 0.84 | GABRA2 (0.43) | CA1CA2CA9CA4THRB | |
| SCHEMBL724319 | 0.84 | MAPT (0.45) | CA1CA2CA9CA4MEN1 | |
| SCHEMBL15151734 | 0.83 | GABRA2 (0.46) | CA1CA2CA9CA4HTT | |
| SCHEMBL725514 | 0.81 | CNR2 (0.41) | CA1CA2CA9CA4HTR6 | |
| SCHEMBL724744 | 0.81 | GABRA2 (0.44) | CA1CA2CA9CA4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10022356-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022356-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-01-21 | — | — | US | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CA1 3550/4885CA2 2153/4885CA9 336/4885 |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | BRAF, NRAS, RAF1 | CA1 4764/4885CA2 3379/4885CA9 3080/4885 |
| US-10022356-B2 | Compounds for treatment of cancer | BRAF, NRAS, RAF1 | CA1 4764/4885CA2 3379/4885CA9 3080/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CA1 3550/4885CA2 2153/4885CA9 336/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CA1 800/4885CA2 1383/4885CA9 171/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CA1 800/4885CA2 1383/4885CA9 171/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | CA1 3550/4885CA2 2153/4885CA9 336/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CA1 3550/4885CA2 2153/4885CA9 336/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CA1 3550/4885CA2 2153/4885CA9 336/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CA1 3550/4885CA2 2153/4885CA9 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.